

Gastroenterology

TABLE OF
CONTENTS

Volume 169 / Issue 6

November 2025

www.gastrojournal.org

Contents

ON THE COVER

Gastroenterology



Reassessing Barrett's Esophagus Surveillance. See article by Old, et al, page 1233 for additional information.

COMMENTARIES

1097 A Practical Guide to Incorporating a Psychologist Into a Gastroenterology Practice

J. K. Salwen-Deremer, S. Ballou, M. Petrik, M. Regueiro, C. A. Siegel, L. Keefer, and GastroPsych Business Plan Working Group

1103 Emerging Role of Phosphatidylethanol Testing in Clinical Practice for the Identification of Steatotic Liver Disease Subtypes: Is This the New Standard?

R. Loomba, H. Hagström, and L. A. Díaz

DIVERSITY, EQUITY, AND INCLUSION IN GI

1108 Strategies to Promote Health Equity in Professional Society Clinical Guidance in Gastroenterology

S. M. Siddique, P. A. Hart, O. Altayyar, S. M. Quezada, S. Singh, and S. Sultan

MENTORING, EDUCATION, AND TRAINING CORNER

1112 A Learner's Guide to Optical Diagnosis in Endoscopy: Training Strategies and Practical Applications

R. Bechara, M. A. Scaffidi, and S. C. Grover

EDITORIALS

1116 Endoscopic Surveillance for Nondysplastic Barrett's Esophagus: Are We Violating "Primum Non Nocere"?

S. N. Van Munster, J. J. G. H. M. Bergman, and J. M. Inadomi

See Old O et al on page 1233; and Deidda M et al on page 1244.

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2025 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

1119 Unmasking Treatment Efficacy: A Consensus Blueprint for Steroid Stewardship in Inflammatory Bowel Disease Trials

A. Lahat

See Hanžel J et al on page 1282.

GASTRO CURBSIDE CONSULT

1122 A Rare Cause of Abdominal Pain and Melena

B. Liu and F. Guan

1125 Fatigue, Weakness, Shoulder Pains After Achieving Remission for 8 Years: A Rare Case With an Even More Unusual Presentation

X.-Q. He, Z. Yang, and G.-X. Hu

1130 Mis-Lead by Obstruction

A. Jhahharia, D. Shah, and P. Ashdhir

1134 A Rare Cause of Abdominal Distension in Infancy

Y.-S. Chen, J.-H. Weng, and S.-M. Chen

GASTRO GRAND ROUNDS

1139 Navigating the Differential Diagnosis of Intestinal Tuberculosis and Crohn's Disease

V. Pratap Mouli, S. Kedia, V. Sharma, A. B. Pulimood, R. Sharma, and V. Ahuja

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

1147 In Our Scope of Practice: Genetic Risk Assessment and Testing for Gastrointestinal Cancers and Polyposis in Gastroenterology

K. Monahan, H. Hampel, E. Stoffel, and S. S. Kupfer

1166 Role of Noninvasive Imaging in the Diagnosis and Management of Patients With Suspected and Established Inflammatory Bowel Disease

T. Kucharzik, M. Allocca, J. Torres, and S. A. Taylor

GUIDELINES

1184 AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus

S. Wani, M. J. Zhou, T. Sawas, J. H. Rubenstein, S. Eluri, D. A. Leiman, S. Sultan, S. Singh, J. Inadomi, A. P. Thrift, D. A. Katzka, and P. Davitkov

1232 Spotlight: High Quality Endoscopic Exam for Barrett's Esophagus

S. Eluri, S. Wani, M. J. Zhou, T. Sawas, J. H. Rubenstein, D. A. Leiman, A. P. Thrift, S. Sultan, S. Singh, J. Inadomi, D. A. Katzka, and P. Davitkov

ORIGINAL RESEARCH

Full Reports

Esophagus

1233 Barrett's Oesophagus Surveillance Versus Endoscopy at Need Study (BOSS): A Randomized Controlled Trial

O. Old, J. Jankowski, S. Attwood, C. Stokes, C. Kendall, C. Rasdell, A. Zimmermann, M. S. Massa, S. Love, S. Sanders, M. Deidda, A. Briggs, J. Hapeshi, C. Foy, P. Moayyedi, and H. Barr, on behalf of the BOSS Trial Team

See editorial on page 1116.

Patients with Barrett's esophagus are at increased risk of esophageal adenocarcinoma; however, scheduled endoscopy every 2 years did not reduce their risk of death or their risk of esophageal adenocarcinoma.

1244 **Cost-Effectiveness of Regular Surveillance Versus Endoscopy at Need for Patients With Barrett's Esophagus: Economic Evaluation Alongside the Barrett's Oesophagus Surveillance Study (BOSS) Randomized Controlled Trial**

M. Deidda, O. Old, J. Jankowski, S. Attwood, C. Stokes, C. Kendall, C. Rasdell, A. Zimmermann, S. Massa, S. Love, S. Sanders, J. Hapeshi, C. Foy, A. Briggs, H. Barr, and P. Moayyedi, on behalf of the BOSS Trial team

See editorial on page 1116.

An economic model was created that shows that current Barrett's guidelines are too expensive for the benefits gained. Future guidelines need to focus on those at highest risk of esophageal cancer.

Small Bowel

1253 **Blood-Based T-Cell Diagnosis of Celiac Disease**

O. G. Moscatelli, A. K. Russell, L. M. Henneken, L. Fothergill, A. Motyer, H. Reid, J. Rossjohn, V. Bryant, R. P. Anderson, M. Y. Hardy, and J. A. Tye-Din

A simple blood test measuring the marker interleukin 2 in a blood sample shows high accuracy in diagnosing celiac disease and works even in people consuming a gluten-free diet.

1268 **Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis**

C.-H. Chiang, A. Jaroenlapnopparat, S. C. Colak, C.-C. Yu, N. Xanthavanij, T.-H. Wang, X. Y. See, S.-W. Lo, A. Ko, Y.-C. Chang, J. Song, Y. P. Hsia, and C.-H. Chiang

Glucagon-like peptide-1 receptor agonists increase the risk of gallstones and acid reflux, but not other gastrointestinal or biliary-related complications.

Inflammatory Bowel Disease

1282 **An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease**

J. Hanžel, V. Solitano, S. K. Vuyyuru, R. Panaccione, B. E. Sands, L. Peyrin-Biroulet, S. Danese, G. R. D'Haens, R. Atreya, M. Allez, C. N. Bernstein, P. Bossuyt, B. Bressler, R. V. Bryant, B. L. Cohen, J.-F. Colombel, F. D'Amico, A. Dignass, M. Dubinsky, P. Fleshner, R. B. Gearry, S. B. Hanauer, A. L. Hart, M. Kayal, T. Kucharzik, P. L. Lakatos, E. Louis, F. Magro, N. Narula, R. W. Leong, J. Panés, T. Raine, Z. Ran, M. D. Regueiro, W. Reinisch, S. Singh, A. H. Steinhart, S. Travis, R. C. Ungaro, C. J. van der Woude, T. Yamamoto, V. Ahuja, D. T. Rubin, P. S. Dulai, L. J. Cornfield, M. Hogan, W. J. Sandborn, B. G. Feagan, V. Jairath, and C. Ma

See editorial on page 1119.

Recommendations from a consensus of international experts on the appropriate use of corticosteroids in inflammatory bowel disease clinical trials to improve consistency with clinical care are summarized.

RESEARCH LETTERS

1294 **Mild Crohn's Disease Is Associated With Altered Sphingolipid Metabolism and Reduced Neutrophilic Inflammation**

A. R. Bourgonje, S. Ibing, P. Rajauria, J. Peraza, The Mild CD Investigation Consortium, J.-F. Colombel, and R. C. Ungaro

1298 **Risk-Adapted Starting Ages for Colorectal Cancer Screening Based on Comprehensive Family History**

T. Seum, M. Hoffmeister, and H. Brenner

1301 **Colonoscopic Follow-Up After Abnormal Blood-Based Colorectal Cancer Screening Results**

T. A. Zaki, N. J. Zhang, S. P. Forbes, V. M. Raymond, A. K. Das, and F. P. May

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

e1 **CME Exam 1: Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis**

GASTRO DIGEST

- 1304 Unraveling the Genetic Mosaic of Congenital Enteropathies**
D. Kotlarz
- 1305 Early-Life Colibactin Exposure Is Associated With Early-Onset Colorectal Cancer Occurrence**
A. Severino and G. Ianaro
- 1305 Yields and Completion Rates of Colorectal Cancer Screening Modalities in Patients Aged 45–50**
N. Forbes

- 1306 High-Flow Nasal Cannula Oxygen Therapy Reduces the Incidence of Hypoxia During Deeply Sedated Endoscopy**
R. Khan

CORRESPONDENCE

- 1308 Thoughts on Colorectal Cancer and Family Polyp History**
H. Cai, X. Si, and K. Zhao
- 1309 Insights on the Relationship Between Risk of Colorectal Cancer and the Frequency of Colorectal Polyp Diagnosis in Relatives**
X. Shi and J. Chen
- 1309 Advancing Risk Stratification in Familial Colorectal Cancer: A Call for More Comprehensive Assessment**
X. Wang, Y. Xu, R. Wu, and H. Zhang
- 1310 Further Exploration of the Frequency of Polyp Diagnosis in Relatives and the Risk of Colorectal Cancer**
S. Jing and J. Song
- 1311 Familial Aggregation of Colorectal Polyps: Disentangling Surveillance Effects From Genetic Predisposition**
C. Dong, C. Pang, Z. Wei, and C. Liang
- 1312 Reply**
Y. Hu, E. Kharazmi, and M. Fallah
- 1313 Further Dimensions of the Role of TREM2 in Pancreatic Ductal Adenocarcinoma**
C. Zhang
- 1314 Reply**
Y. Chen
- 1315 Beyond County Boundaries: Rethinking Gastroenterology Access Metrics in the United States**
J. Wei, Y. Wu, Y. Li, and J. Li
- 1316 Reply**
L. Yao, X. Ying, and A. B. Jesudian
- 1317 Visualization Score Might Be Considered for Hepatocellular Carcinoma Surveillance**
X. Shi

- 1318 Noncontrast MRI in Hepatocellular Carcinoma Surveillance: Considerations for Implementation in Clinical Practice**
Y. Wang, Y. Huang, G. Zhang, S. Wang, and N. Li
- 1319 Thoughts on "Noncontrast Magnetic Resonance Imaging vs Ultrasonography for Hepatocellular Carcinoma Surveillance"**
V. M. Fernández-Garibay and N. C. Chávez-tapia
- 1319 Reply**
H. Rhee, M.-J. Kim, and D. Y. Kim
- 1321 Standardizing FLIP Interpretation: From Classification to Calibration, Quantification, and Predictive Utility**
Z. Chen, X. Cai, and H. Jiang
- 1321 The Contractility Pattern at Volume <50 mL in the Dallas Consensus for Interpretation of FLIP Panometry**
S. Samo
- 1322 Reply**
D. A. Carlson, J. E. Pandolfino, and V. J. A. Konda
- 1323 MGPT in Advanced Adenomas: Predictive, Actionable, or Premature?**
M.-J. Wang and F. Chen
- 1324 Reply**
S. G. Patel, A. Bansal, and M. Springer
- 1325 The Exclusion Diet Conundrum: Are We Separating the Wheat From the Chaff?**
C. Van De Bruaene, K. Raymenants, L. Balsiger, K. Routhiaux, H. Soliman, and T. Vanuytsel
- 1326 Methodological Limitations in IgG-Based Elimination Diet for IBS**
M.-C. Wu, P. Kuo, and J. C.-C. Wei
- 1327 Caution Warranted in the Clinical Translation of IgG-Based Elimination Diets for IBS**
X. Wu and B. Lu
- 1327 IgG-Guided Diets for IBS: Addressing Critical Questions of Evidence and Clinical Utility**
Y.-Q. Chen, K.-Y. Xu, Y.-S. Gao, and X.-Q. Bai
- 1329 Reply**
P. Singh, W. D. Chey, and A. Lembo
- 1330 Comments on "Use of Fecal Immunochemical Testing for Risk Stratification of Patients With Symptoms of Colorectal Cancer Referred for Diagnostic Colonoscopy"**
Q. Long, Y. Wen, and J. Li
- 1331 Editors' Note**